Journal article
Formulary Drug Review: Etelcalcetide
Hospital pharmacy (Philadelphia), Vol.52(10), pp.669-674
11/2017
Handle:
https://hdl.handle.net/2376/105942
PMCID: PMC5735746
PMID: 29276237
Abstract
Each month, subscribers to
The Formulary Monograph Service
receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of
The Formulary, Hospital Pharmacy
publishes selected reviews in this column. For more information about
The Formulary Monograph Service
, contact Wolters Kluwer customer service at 866-397-3433. The November 2017 monograph topics are Ertugliflozin, Glecaprevir / pibrentasvir, Neratinib, Sofosbuvir, velpatasvir, voxilaprevir and SQ C1 esterase inhibitor. The MUE is on glecaprevir, pibrentasvir.
Metrics
9 Record Views
Details
- Title
- Formulary Drug Review: Etelcalcetide
- Creators
- Danial E Baker - Washington State University, Spokane, WA, USA
- Publication Details
- Hospital pharmacy (Philadelphia), Vol.52(10), pp.669-674
- Academic Unit
- Pharmacotherapy, Department of
- Publisher
- SAGE Publications; Sage CA: Los Angeles, CA
- Identifiers
- 99900546854001842
- Language
- English
- Resource Type
- Journal article